Colloidal Gold Immunochromatographic Assay (GICA) is an Effective Screening Method for Identifying Detectable Anti-Sars-cov-2 Neutralizing Antibodies

Xinjie Li,Yue Yin,Ling Pang,Shuyun Xu,Fengmin Lu,Dong Xu,Tao Shen
DOI: https://doi.org/10.1016/j.ijid.2021.05.080
IF: 12.073
2021-01-01
International Journal of Infectious Diseases
Abstract:Introduction: A large number of COVID-19 patients are in recovery, and millions of people are vaccinated for COVID-19 globally. This calls for a rapid screening strategy of SARS-CoV-2 protective antibodies, generated in rehabilitated and vaccinated populations. Methods: Serum samples collected over a follow-up period of six months from 306 COVID-19 cases discharged from Wuhan Tongji Hospital were analyzed. Anti-S Abs were detected by colloidal gold immunochromatographic assay (GICA), and neutralizing antibodies (nAbs) were detected by chemiluminescent microparticle immunoassay (CMIA). Results: Most COVID-19 survivors tested positive for anti-S Abs (83.7%) and nAbs (98.0%) 6 months after being discharged from the hospital, and the levels of anti-S Abs in the blood were highly positively correlated with nAbs (r = 0.652, P < 0.0001). The positivity rate of nAbs for patients with anti-S Abs positive was 100%. Conclusions: There is a good agreement between anti-S Abs detected by GICA and nAbs detected by CMIA. It indicates that anti-S Abs detected by GICA may be used as a cheaper screening strategy for detectable SARS-CoV-2 nAbs in COVID-19 convalescent individuals.
What problem does this paper attempt to address?